169 related articles for article (PubMed ID: 36855786)
1. Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of
Li JH; Wu X; Ni X; Li YX; Xu L; Hao XY; Zhao W; Zhu XX; Yin XY
Clin Transl Med; 2023 Mar; 13(3):e1213. PubMed ID: 36855786
[TBL] [Abstract][Full Text] [Related]
2. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
[No Abstract] [Full Text] [Related]
3. Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance.
Ravichandra A; Bhattacharjee S; Affò S
Adv Cancer Res; 2022; 156():201-226. PubMed ID: 35961700
[TBL] [Abstract][Full Text] [Related]
4. Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition.
Mancarella S; Gigante I; Serino G; Pizzuto E; Dituri F; Valentini MF; Wang J; Chen X; Armentano R; Calvisi DF; Giannelli G
J Exp Clin Cancer Res; 2022 Nov; 41(1):331. PubMed ID: 36443822
[TBL] [Abstract][Full Text] [Related]
5. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase.
Lin Y; Cai Q; Chen Y; Shi T; Liu W; Mao L; Deng B; Ying Z; Gao Y; Luo H; Yang X; Huang X; Shi Y; He R
Hepatology; 2022 Jan; 75(1):28-42. PubMed ID: 34387870
[TBL] [Abstract][Full Text] [Related]
6. Automated Analysis for the Prevalence of Cancer-Associated Fibroblasts in Resected Specimens of Intrahepatic Cholangiocarcinoma is a Simple and Reliable Evaluation System.
Eguchi S; Yamada D; Kobayashi S; Sasaki K; Iwagami Y; Tomimaru Y; Noda T; Takahashi H; Asaoka T; Tanemura M; Doki Y; Eguchi H
Ann Surg Oncol; 2023 Sep; 30(9):5420-5428. PubMed ID: 37222943
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol interrupts the pro-invasive communication between cancer associated fibroblasts and cholangiocarcinoma cells.
Thongchot S; Ferraresi A; Vidoni C; Loilome W; Yongvanit P; Namwat N; Isidoro C
Cancer Lett; 2018 Aug; 430():160-171. PubMed ID: 29802929
[TBL] [Abstract][Full Text] [Related]
8. HS6ST1 overexpressed in cancer-associated fibroblast and inhibited cholangiocarcinoma progression.
Hu S; Xia C; Zou H; Ren W; Liu L; Wang L; Kang Q; He K; Wang T; Zhang X
Dig Liver Dis; 2023 Aug; 55(8):1114-1125. PubMed ID: 36586771
[TBL] [Abstract][Full Text] [Related]
9. DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti-DKK1 therapeutic DKN-01.
Jarman EJ; Horcas-Lopez M; Waddell SH; MacMaster S; Gournopanos K; Soong DYH; Musialik KI; Tsokkou P; Ng ME; Cambridge WA; Wilson DH; Kagey MH; Newman W; Pollard JW; Boulter L
Liver Int; 2023 Jan; 43(1):208-220. PubMed ID: 35924447
[TBL] [Abstract][Full Text] [Related]
10. Unveiling the role of HP1α-HDAC1-STAT1 axis as a therapeutic target for HP1α-positive intrahepatic cholangiocarcinoma.
Xiong F; Wang D; Xiong W; Wang X; Huang WH; Wu GH; Liu WZ; Wang Q; Chen JS; Kuai YY; Wang B; Chen YJ
J Exp Clin Cancer Res; 2024 May; 43(1):152. PubMed ID: 38812060
[TBL] [Abstract][Full Text] [Related]
11. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
Bath NM; Pawlik TM
Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354
[TBL] [Abstract][Full Text] [Related]
12. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.
Heits N; Heinze T; Bernsmeier A; Kerber J; Hauser C; Becker T; Kalthoff H; Egberts JH; Braun F
BMC Cancer; 2016 May; 16():322. PubMed ID: 27206490
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts.
Yamanaka T; Harimoto N; Yokobori T; Muranushi R; Hoshino K; Hagiwara K; Gantumur D; Handa T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Shirabe K
Br J Cancer; 2020 Mar; 122(7):986-994. PubMed ID: 32015511
[TBL] [Abstract][Full Text] [Related]
14. Sequentially targeting and intervening mutual Polo-like Kinase 1 on CAFs and tumor cells by dual targeting nano-platform for cholangiocarcinoma treatment.
Zhou Y; Xu L; Wang Z; Liu H; Zhang X; Shu C; Zhang M; Wang T; Xu X; Pu X; He J; Wang P; Qiu Y; Xu G; Zou X; Zhu Y; Wang L
Theranostics; 2022; 12(8):3911-3927. PubMed ID: 35664077
[No Abstract] [Full Text] [Related]
15. Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice.
Wabitsch S; Tandon M; Ruf B; Zhang Q; McCallen JD; McVey JC; Ma C; Green BL; Diggs LP; Heinrich B; Greten TF
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1166-1178. PubMed ID: 34033968
[TBL] [Abstract][Full Text] [Related]
16. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
[TBL] [Abstract][Full Text] [Related]
17. MFAP5 facilitates the aggressiveness of intrahepatic Cholangiocarcinoma by activating the Notch1 signaling pathway.
Li JH; Zhu XX; Li FX; Huang CS; Huang XT; Wang JQ; Gao ZX; Li SJ; Xu QC; Zhao W; Yin XY
J Exp Clin Cancer Res; 2019 Nov; 38(1):476. PubMed ID: 31775892
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein.
Saikawa S; Kaji K; Nishimura N; Seki K; Sato S; Nakanishi K; Kitagawa K; Kawaratani H; Kitade M; Moriya K; Namisaki T; Mitoro A; Yoshiji H
Cancer Lett; 2018 Oct; 434():120-129. PubMed ID: 30031758
[TBL] [Abstract][Full Text] [Related]
19. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
Zen Y
Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
[TBL] [Abstract][Full Text] [Related]
20. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]